Human insulin prepared with the aid of recombinant DNA
Krans, H.M.
Nederlands Tijdschrift Voor Geneeskunde 125(21): 840-842
1981
ISSN/ISBN: 0028-2162 PMID: 7017431 Document Number: 171845
Document emailed within 1 workday
Related Documents
Rosas Vargas, M.A.; Alvarez Amador, M.; Alvarez Amador, L.M.; del Río Navarro, B.E.; Avila Castanón, L.; Sienra Monge, J.J. 2001: Desensitization to human recombinant DNA insulin in an adolescent with insulin-dependent diabetes mellitus Revista Alergia Mexico 48(5): 129-132Morgan, J.M.; Piraino, A.J.; Saris, S.D.; Capuzzi, D.M. 1994: Pharmacodynamics of a continuous intravenous infusion of CGP-35126 recombinant human insulin-like growth factor-I (rhIGF-I) on glucose and insulin levels in healthy males International Journal of Clinical Pharmacology and Therapeutics 32(5): 235-239
Takano, K.; Hizuka, N.; Shizume, K.; Asakawa, K.; Fukuda, I.; Demura, H. 1991: Repeated sc administration of recombinant human insulin-like growth factor i (IGF-I) to human subjects for 7 days Growth Regulation 1(1): 23-28
Kato, M. 1998: Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes Hokkaido Journal of Medical Science 73(6): 613-625
Galloway, J.A. 1985: Highlights of clinical experiences with recombinant human insulin (rDNA) and human proinsulin (rDNA) Netherlands Journal of Medicine 28 Suppl. 1: 37-42
Xia, H.Z.; Du, Z.; Craig, S.; Klisch, G.; Noben-Trauth, N.; Kochan, J.P.; Huff, T.H.; Irani, A.M.; Schwartz, L.B. 1997: Effect of recombinant human IL-4 on tryptase, chymase, and Fc epsilon receptor type i expression in recombinant human stem cell factor-dependent fetal liver-derived human mast cells Journal of Immunology 159(6): 2911-2921
Kownatzki, E.; Kapp, A.; Uhrich, S. 1988: Modulation of human neutrophilic granulocyte functions by recombinant human tumor necrosis factor and recombinant human lymphotoxin. Promotion of adherence, inhibition of chemotactic migration and superoxide anion release from adherent cells Clinical and Experimental Immunology 74(1): 143-148
Ottmann, O.G.; Abboud, M.; Welte, K.; Souza, L.M.; Pelus, L.M. 1989: Stimulation of human hematopoietic progenitor cell proliferation and differentiation by recombinant human interleukin 3. Comparison and interactions with recombinant human granulocyte-macrophage and granulocyte colony-stimulating factors Experimental Hematology 17(2): 191-197
Bialas, T.; Kolitz, J.; Levi, E.; Polivka, A.; Oez, S.; Miller, G.; Welte, K. 1988: Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin Cancer Research 48(4): 891-898
Hamaguchi, T.; Sadahiro, K.; Satoh, T. 2015: Current concept of insulin therapy intensification, and the role of human regular insulin and rapid-acting insulin analogs in insulin treatment Nihon Rinsho. Japanese Journal of Clinical Medicine 73(3): 447-452
Abbruzzese, J.L.; Levin, B.; Ajani, J.A.; Faintuch, J.S.; Saks, S.; Patt, Y.Z.; Edwards, C.; Ende, K.; Gutterman, J.U. 1989: Phase i trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer Cancer Research 49(14): 4057-4061
Froesch, E.R. 1995: From research of non-suppressible serum insulin activity to the clinical application of recombinant insulin-like growth factor (rhIGF-I) Schweizerische Medizinische Wochenschrift 125(27-28): 1326-1335
Che, T.-t.; Wang, X.; Liu, Y.-y.; Tian, H.-m.; Yang, G.-y.; Xu, M.; Xiao, C.-q.; Zhu, L.ü-y.; Lü, X.-f.; Yu, H.-l.; Zhang, X.-x.; Ren, Y. 2011: The efficacy and safety of recombinant human insulin injection in the treatment of diabetic patients:a multicenter, randomized, controlled and open-labeled clinical trial Zhonghua Nei Ke Za Zhi 50(1): 23-26
Butler, A.A.; Blakesley, V.A.; Poulaki, V.; Tsokos, M.; Wood, T.L.; LeRoith, D.; Pouliki, V. 1998: Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression Cancer Research 58(14): 3021-3027
Waldhäusl, W.K.; Gasić, S.; Bratusch-Marrain, P.; Korn, A.; Nowotny, P. 1982: Feedback inhibition by biosynthetic human insulin of insulin release in healthy human subjects American Journal of Physiology 243(6): E476-E482
Holloway, C.J. 1994: Applications of recombinant DNA technology in the production of glycosylated recombinant human granulocyte colony stimulating factor European Journal of Cancer 30a Suppl 3: S2-S6
Négrier, C.; Shapiro, A.; Berntorp, E.; Pabinger, I.; Tarantino, M.; Retzios, A.; Schroth, P.; Ewenstein, B. 2008: Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients Thrombosis and Haemostasis 100(2): 217-223
Kemmer, F.W.; Sonnenberg, G.E.; Cüppers, H.J.; Berger, M. 1983: Absorption kinetics of semisynthetic human insulin and biosynthetic human insulin Münchener Medizinische Wochenschrift 1: S85-S90
Espevik, T.; Figari, I.S.; Ranges, G.E.; Palladino, M.A. 1988: Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1 Journal of Immunology 140(7): 2312-2316
Jungmann, E. 1997: From human insulin to designer insulin. Why insulin analogs? Fortschritte der Medizin 115(12): 40-41